Nuo Therapeutics’ Aurix System added to WCA formulary

Nuo Therapeutics announces that Wound Care Advantage, WCA, the nation’s leading wound care consulting firm has added the Aurix System to its formulary. Wound Care Advantage has established a large network of successful wound healing programs with partner hospitals. Through a strong commitment to quality care and innovation, WCA has built financially sustainable wound care programs that have saved limbs and lives of more than 40,000 patients suffering chronic wounds. “Diabetic foot ulcers pose a significant risk to patients and can be challenging for wound care centers to treat from both clinical and financial perspectives,” commented Dave Hazard, Nuo’s Vice President of Sales. “With thousands of commercially available wound care products, it can be extremely difficult for wound care centers to identify products that are both reimbursed by Medicare, and more importantly, that actually heal patients. We are excited to partner with Wound Care Advantage’s team of experts who rigorously vet each product that is placed on the formulary.”

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on AURX:

Disclaimer & DisclosureReport an Issue